News | March 18, 2026
Zydus, Lupin join forces to expand access to semaglutide in India
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The company announced positive topline data from the Phase 3 ADorable-1 trial
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial will enroll up to 42 patients in Finland across four cohorts
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Subscribe To Our Newsletter & Stay Updated
